Preclinical CRO Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Description

A recent market analysis report by Fairfield Market Research reveals that the global Preclinical Contract Research Organization (CRO) market achieved sales of US$ 5.9 billion in 2024. The market is poised to attain a valuation of US$ 12 billion by 2031. Toxicology Testing is anticipated to be the leading revenue-generating segment during forecast period 2024 to 2031.

Factors Impacting the Preclinical CRO Market

Regulatory Constraints: Stringent regulatory norms for preclinical CRO services, including Good Laboratory Practice (GLP) regulations established by organizations like the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), can pose challenges to the industry. Compliance with quality control standards is essential but may restrict market expansion, as certain advanced tests like genotoxicity are often conducted in-house by pharmaceutical companies due to regulatory requirements.

Rise of Biopharmaceutical Companies: The surge in biopharmaceutical companies worldwide, especially in developing and emerging countries, has led to an increased demand for preclinical CRO services. Smaller biopharmaceutical companies, lacking the resources and expertise for in-house preclinical research, are outsourcing these activities to preclinical CROs. The growing number of biopharmaceutical companies is a significant driver of the global preclinical CRO market.

Increased Disease Burden: The rising prevalence of diseases has prompted a growing demand for clinical tools and diagnostic equipment that can provide quick and reliable results while being safe. This trend has further boosted the demand for preclinical CRO services, particularly from medical device companies, contributing to the growth of the market.

Region-wise Analysis

North America: North America presents substantial opportunities in the preclinical CRO market. Increased research and development investments, along with rapid adoption of new technologies, are expected to drive significant market growth in the region. The availability of skilled workforce and affordable equipment costs are additional factors fueling market expansion. The region is also witnessing a rising burden of chronic diseases, further driving demand for preclinical CRO services.

Asia Pacific: The Asia Pacific region is poised for rapid growth due to the cost-effectiveness of preclinical CRO services in countries like India and China. The establishment of numerous contract research organizations (CROs) in the region has strengthened the preclinical outsourcing industry. For instance, Singapore hosts several contract research organizations that cater to the growing needs of pharmaceutical and biopharmaceutical companies.

Category-wise Insights

Toxicology Testing: The Toxicology Testing segment is projected to grow at a CAGR of 10% during the forecast period. The rise in outsourcing of noncore preclinical CRO studies and increased adoption of toxicology tests are driving this growth. The dynamic growth in the biopharmaceutical and pharmaceutical sectors, coupled with the demand for new drugs and chemicals, is expected to further propel the market. Toxicology Testing plays a vital role in Investigational New Drug (IND)-enabling studies, contributing significantly to the segment's growth.

Competitive Landscape

The rapid adoption of advanced healthcare technologies to enhance healthcare delivery is a key factor driving competitiveness in the market. Leading firms are pursuing mergers, acquisitions, and new product launches to maintain market share and diversify their product portfolios. In response to the ongoing COVID-19 pandemic, major market participants are offering various services to address the challenging conditions.

Key Companies Profiled

Eurofins Scientific
PRA Health Sciences
Medpace
Pharmaceutical Product Development
ICON Plc
Wuxi Apptec
MPI Research

Market Segments Covered in Preclinical CRO Market Analysis

By Service Type

Bioanalysis and DMPK studies
- In vitro ADME
- In-vivo PK

Toxicology Testing
- GLP
- Non-GLP

Compound Management
- Process Research and Development
- Custom Synthesis
- Other Compound Management

Chemistry
- Medicinal Chemistry
- Computation Chemistry
  - Safety Pharmacology
  - Other Service Types

By End-use

Biopharmaceutical Companies
Government and Academic Institutes
Medical Device Companies

By Region

North America
Latin America
Europe
APAC
MEA

1. Executive Summary

1.1. Global Preclinical CRO Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter's Five Forces Analysis
2.5. COVID-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
- 2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Global Preclinical CRO Market Outlook, 2018 - 2031

3.1. Global Preclinical CRO Market Outlook, by Service Type, Value (US$ Bn), 2018 - 2031
- 3.1.1. Key Highlights
  - 3.1.1.1. Bioanalysis and DMPK studies
    - 3.1.1.1.1. In vitro ADME
    - 3.1.1.1.2. In-vivo PK
  - 3.1.1.2. Toxicology Testing
    - 3.1.1.2.1. GLP
    - 3.1.1.2.2. Non-GLP
  - 3.1.1.3. Compund Management
    - 3.1.1.3.1. Process R&D
    - 3.1.1.3.2. Custom Synthesis
    - 3.1.1.3.3. Other Compound Management
  - 3.1.1.4. Chemistry
    - 3.1.1.4.1. Medicinal Chemistry
    - 3.1.1.4.2. Computation Chemistry
  - 3.1.1.5. Safety Pharmacology
  - 3.1.1.6. Other Service Types
3.2. Global Preclinical CRO Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
- 3.2.1. Key Highlights
  - 3.2.1.1. Biopharmaceutical Companies
  - 3.2.1.2. Government and Academic Institutes
  - 3.2.1.3. Medical Device Companies
3.3. Global Preclinical CRO Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
- 3.3.1. Key Highlights
  - 3.3.1.1. North America
  - 3.3.1.2. Europe
  - 3.3.1.3. Asia Pacific
  - 3.3.1.4. Latin America
  - 3.3.1.5. Middle East & Africa

4. North America Preclinical CRO Market Outlook, 2018 - 2031

4.1. North America Preclinical CRO Market Outlook, by Service Type, Value (US$ Bn), 2018 - 2031
- 4.1.1. Key Highlights
  - 4.1.1.1. Bioanalysis and DMPK studies
    - 4.1.1.1.1. In vitro ADME
    - 4.1.1.1.2. In-vivo PK
  - 4.1.1.2. Toxicology Testing
    - 4.1.1.2.1. GLP
    - 4.1.1.2.2. Non-GLP
  - 4.1.1.3. Compund Management
    - 4.1.1.3.1. Process R&D
    - 4.1.1.3.2. Custom Synthesis
    - 4.1.1.3.3. Other Compound Management
  - 4.1.1.4. Chemistry
    - 4.1.1.4.1. Medicinal Chemistry
    - 4.1.1.4.2. Computation Chemistry
  - 4.1.1.5. Safety Pharmacology
  - 4.1.1.6. Other Service Types
4.2. North America Preclinical CRO Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
- 4.2.1. Key Highlights
  - 4.2.1.1. Biopharmaceutical Companies
  - 4.2.1.2. Government and Academic Institutes
  - 4.2.1.3. Medical Device Companies
- 4.2.2. BPS Analysis/Market Attractiveness Analysis
4.3. North America Preclinical CRO Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 4.3.1. Key Highlights
  - 4.3.1.1. U.S. Preclinical CRO Market by Service Type, Value (US$ Bn), 2018 - 2031
  - 4.3.1.2. U.S. Preclinical CRO Market by End User, Value (US$ Bn), 2018 - 2031
  - 4.3.1.3. Canada Preclinical CRO Market by Service Type, Value (US$ Bn), 2018 - 2031
  - 4.3.1.4. Canada Preclinical CRO Market by End User, Value (US$ Bn), 2018 - 2031
- 4.3.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Preclinical CRO Market Outlook, 2018 - 2031

5.1. Europe Preclinical CRO Market Outlook, by Service Type, Value (US$ Bn), 2018 - 2031
- 5.1.1. Key Highlights
  - 5.1.1.1. Bioanalysis and DMPK studies
    - 5.1.1.1.1. In vitro ADME
    - 5.1.1.1.2. In-vivo PK
  - 5.1.1.2. Toxicology Testing
    - 5.1.1.2.1. GLP
    - 5.1.1.2.2. Non-GLP
  - 5.1.1.3. Compund Management
    - 5.1.1.3.1. Process R&D
    - 5.1.1.3.2. Custom Synthesis
    - 5.1.1.3.3. Other Compound Management
  - 5.1.1.4. Chemistry
    - 5.1.1.4.1. Medicinal Chemistry
    - 5.1.1.4.2. Computation Chemistry
  - 5.1.1.5. Safety Pharmacology
  - 5.1.1.6. Other Service Types
5.2. Europe Preclinical CRO Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
- 5.2.1. Key Highlights
  - 5.2.1.1. Biopharmaceutical Companies
  - 5.2.1.2. Government and Academic Institutes
  - 5.2.1.3. Medical Device Companies
- 5.2.2. BPS Analysis/Market Attractiveness Analysis
5.3. Europe Preclinical CRO Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 5.3.1. Key Highlights
  - 5.3.1.1. Germany Preclinical CRO Market by Service Type, Value (US$ Bn), 2018 - 2031
  - 5.3.1.2. Germany Preclinical CRO Market by End User, Value (US$ Bn), 2018 - 2031
  - 5.3.1.3. U.K. Preclinical CRO Market by Service Type, Value (US$ Bn), 2018 - 2031
  - 5.3.1.4. U.K. Preclinical CRO Market by End User, Value (US$ Bn), 2018 - 2031
  - 5.3.1.5. France Preclinical CRO Market by Service Type, Value (US$ Bn), 2018 - 2031
  - 5.3.1.6. France Preclinical CRO Market by End User, Value (US$ Bn), 2018 - 2031
  - 5.3.1.7. Italy Preclinical CRO Market by Service Type, Value (US$ Bn), 2018 - 2031
  - 5.3.1.8. Italy Preclinical CRO Market by End User, Value (US$ Bn), 2018 - 2031
  - 5.3.1.9. Turkey Preclinical CRO Market by Service Type, Value (US$ Bn), 2018 - 2031
  - 5.3.1.10. Turkey Preclinical CRO Market by End User, Value (US$ Bn), 2018 - 2031
  - 5.3.1.11. Russia Preclinical CRO Market by Service Type, Value (US$ Bn), 2018 - 2031
  - 5.3.1.12. Russia Preclinical CRO Market by End User, Value (US$ Bn), 2018 - 2031
  - 5.3.1.13. Rest of Europe Preclinical CRO Market by Service Type, Value (US$ Bn), 2018 - 2031
  - 5.3.1.14. Rest of Europe Preclinical CRO Market by End User, Value (US$ Bn), 2018 - 2031
- 5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Preclinical CRO Market Outlook, 2018 - 2031

6.1. Asia Pacific Preclinical CRO Market Outlook, by Service Type, Value (US$ Bn), 2018 - 2031
- 6.1.1. Key Highlights
  - 6.1.1.1. Bioanalysis and DMPK studies
    - 6.1.1.1.1. In vitro ADME
    - 6.1.1.1.2. In-vivo PK
  - 6.1.1.2. Toxicology Testing
    - 6.1.1.2.1. GLP
    - 6.1.1.2.2. Non-GLP
  - 6.1.1.3. Compund Management
    - 6.1.1.3.1. Process R&D
    - 6.1.1.3.2. Custom Synthesis
    - 6.1.1.3.3. Other Compound Management
  - 6.1.1.4. Chemistry
    - 6.1.1.4.1. Medicinal Chemistry
    - 6.1.1.4.2. Computation Chemistry
  - 6.1.1.5. Safety Pharmacology
  - 6.1.1.6. Other Service Types
6.2. Asia Pacific Preclinical CRO Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
- 6.2.1. Key Highlights
  - 6.2.1.1. Biopharmaceutical Companies
  - 6.2.1.2. Government and Academic Institutes
  - 6.2.1.3. Medical Device Companies
- 6.2.2. Others BPS Analysis/Market Attractiveness Analysis
6.3. Asia Pacific Preclinical CRO Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 6.3.1. Key Highlights
  - 6.3.1.1. China Preclinical CRO Market by Service Type, Value (US$ Bn), 2018 - 2031
  - 6.3.1.2. China Preclinical CRO Market by End User, Value (US$ Bn), 2018 - 2031
  - 6.3.1.3. Japan Preclinical CRO Market by Service Type, Value (US$ Bn), 2018 - 2031
  - 6.3.1.4. Japan Preclinical CRO Market by End User, Value (US$ Bn), 2018 - 2031
  - 6.3.1.5. South Korea Preclinical CRO Market by Service Type, Value (US$ Bn), 2018 - 2031
  - 6.3.1.6. South Korea Preclinical CRO Market by End User, Value (US$ Bn), 2018 - 2031
  - 6.3.1.7. India Preclinical CRO Market by Service Type, Value (US$ Bn), 2018 - 2031
  - 6.3.1.8. India Preclinical CRO Market by End User, Value (US$ Bn), 2018 - 2031
  - 6.3.1.9. Southeast Asia Preclinical CRO Market by Service Type, Value (US$ Bn), 2018 - 2031
  - 6.3.1.10. Southeast Asia Preclinical CRO Market by End User, Value (US$ Bn), 2018 - 2031
  - 6.3.1.11. Rest of Asia Pacific Preclinical CRO Market by Service Type, Value (US$ Bn), 2018 - 2031
  - 6.3.1.12. Rest of Asia Pacific Preclinical CRO Market by End User, Value (US$ Bn), 2018 - 2031
- 6.3.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Preclinical CRO Market Outlook, 2018 - 2031

7.1. Latin America Preclinical CRO Market Outlook, by Service Type, Value (US$ Bn), 2018 - 2031
- 7.1.1. Key Highlights
  - 7.1.1.1. Bioanalysis and DMPK studies
    - 7.1.1.1.1. In vitro ADME
    - 7.1.1.1.2. In-vivo PK
  - 7.1.1.2. Toxicology Testing
    - 7.1.1.2.1. GLP
    - 7.1.1.2.2. Non-GLP
  - 7.1.1.3. Compund Management
    - 7.1.1.3.1. Process R&D
    - 7.1.1.3.2. Custom Synthesis
    - 7.1.1.3.3. Other Compound Management
  - 7.1.1.4. Chemistry
    - 7.1.1.4.1. Medicinal Chemistry
    - 7.1.1.4.2. Computation Chemistry
  - 7.1.1.5. Safety Pharmacology
  - 7.1.1.6. Other Service Types
7.2. Latin America Preclinical CRO Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
- 7.2.2. BPS Analysis/Market Attractiveness Analysis
7.3. Latin America Preclinical CRO Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 7.3.1. Key Highlights
  - 7.3.1.1. Brazil Preclinical CRO Market by Service Type, Value (US$ Bn), 2018 - 2031
  - 7.3.1.2. Brazil Preclinical CRO Market by End User, Value (US$ Bn), 2018 - 2031
  - 7.3.1.3. Mexico Preclinical CRO Market by Service Type, Value (US$ Bn), 2018 - 2031
  - 7.3.1.4. Mexico Preclinical CRO Market by End User, Value (US$ Bn), 2018 - 2031
  - 7.3.1.5. Argentina Preclinical CRO Market by Service Type, Value (US$ Bn), 2018 - 2031
  - 7.3.1.6. Argentina Preclinical CRO Market by End User, Value (US$ Bn), 2018 - 2031
  - 7.3.1.7. Rest of Latin America Preclinical CRO Market by Service Type, Value (US$ Bn), 2018 - 2031
  - 7.3.1.8. Rest of Latin America Preclinical CRO Market by End User, Value (US$ Bn), 2018 - 2031
- 7.3.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Preclinical CRO Market Outlook, 2018 - 2031

8.1. Middle East & Africa Preclinical CRO Market Outlook, by Service Type, Value (US$ Bn), 2018 - 2031
- 8.1.1. Key Highlights
  - 8.1.1.1. Bioanalysis and DMPK studies
    - 8.1.1.1.1. In vitro ADME
    - 8.1.1.1.2. In-vivo PK
  - 8.1.1.2. Toxicology Testing
    - 8.1.1.2.1. GLP
    - 8.1.1.2.2. Non-GLP
  - 8.1.1.3. Compund Management
    - 8.1.1.3.1. Process R&D
    - 8.1.1.3.2. Custom Synthesis
    - 8.1.1.3.3. Other Compound Management
  - 8.1.1.4. Chemistry
    - 8.1.1.4.1. Medicinal Chemistry
    - 8.1.1.4.2. Computation Chemistry
  - 8.1.1.5. Safety Pharmacology
  - 8.1.1.6. Other Service Types
8.2. Middle East & Africa Preclinical CRO Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
- 8.2.1. Key Highlights
  - 8.2.1.1. Biopharmaceutical Companies
  - 8.2.1.2. Government and Academic Institutes
  - 8.2.1.3. Medical Device Companies
- 8.2.2. BPS Analysis/Market Attractiveness Analysis
8.3. Middle East & Africa Preclinical CRO Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 8.3.1. Key Highlights
  - 8.3.1.1. GCC Preclinical CRO Market by Service Type, Value (US$ Bn), 2018 - 2031
  - 8.3.1.2. GCC Preclinical CRO Market by End User, Value (US$ Bn), 2018 - 2031
  - 8.3.1.3. South Africa Preclinical CRO Market by Service Type, Value (US$ Bn), 2018 - 2031
  - 8.3.1.4. South Africa Preclinical CRO Market by End User, Value (US$ Bn), 2018 - 2031
  - 8.3.1.5. Egypt Preclinical CRO Market by Service Type, Value (US$ Bn), 2018 - 2031
  - 8.3.1.6. Egypt Preclinical CRO Market by End User, Value (US$ Bn), 2018 - 2031
  - 8.3.1.7. Nigeria Preclinical CRO Market by Service Type, Value (US$ Bn), 2018 - 2031
  - 8.3.1.8. Nigeria Preclinical CRO Market by End User, Value (US$ Bn), 2018 - 2031
  - 8.3.1.9. Rest of Middle East & Africa Preclinical CRO Market by Service Type, Value (US$ Bn), 2018 - 2031
  - 8.3.1.10. Rest of Middle East & Africa Preclinical CRO Market by End User, Value (US$ Bn), 2018 - 2031
- 8.3.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

9.1. Manufacturer vs by End User Heatmap
9.2. Company Market Share Analysis, 2023
9.3. Competitive Dashboard
9.4. Company Profiles
- 9.4.1. Eurofins Scientific
  - 9.4.1.1. Company Overview
  - 9.4.1.2. Product Portfolio
  - 9.4.1.3. Financial Overview
  - 9.4.1.4. Business Strategies and Development
- 9.4.2. PRA Health Sciences
  - 9.4.2.1. Company Overview
  - 9.4.2.2. Product Portfolio
  - 9.4.2.3. Financial Overview
  - 9.4.2.4. Business Strategies and Development
- 9.4.3. Medpace
  - 9.4.3.1. Company Overview
- 9.4.4. Product Portfolio
  - 9.4.4.1. Financial Overview
  - 9.4.4.2. Business Strategies and Development
- 9.4.5. Pharmaceutical Product Development
  - 9.4.5.1. Company Overview
  - 9.4.5.2. Product Portfolio
  - 9.4.5.3. Financial Overview
  - 9.4.5.4. Business Strategies and Development
- 9.4.6. Icon Plc
  - 9.4.6.1. Company Overview
  - 9.4.6.2. Product Portfolio
  - 9.4.6.3. Financial Overview
  - 9.4.6.4. Business Strategies and Development
- 9.4.7. Wuxi Apptec
  - 9.4.7.1. Company Overview
  - 9.4.7.2. Product Portfolio
  - 9.4.7.3. Financial Overview
  - 9.4.7.4. Business Strategies and Development
- 9.4.8. MPI Research
  - 9.4.8.1. Company Overview
  - 9.4.8.2. Product Portfolio
  - 9.4.8.3. Financial Overview
  - 9.4.8.4. Business Strategies and Development

10. Appendix

10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations